Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates
HRTXHeron Therapeutics(HRTX) Zacks Investment Research·2024-05-07 22:05

Heron Therapeutics (HRTX) came out with a quarterly loss of 0.02pershareversustheZacksConsensusEstimateofalossof0.02 per share versus the Zacks Consensus Estimate of a loss of 0.08. This compares to loss of 0.27pershareayearago.Thesefiguresareadjustedfornonrecurringitems.Thisquarterlyreportrepresentsanearningssurpriseof750.27 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 75%. A quarter ago, it was expected that this pharmaceutical company would post a loss of 0.15 per share when it actually produced a loss of $0.07, delivering a surprise of 53.33%. Over the last four quarters, the com ...